Alzamend Neuro
ALZN
20 hedge funds and large institutions have $4.01M invested in Alzamend Neuro in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 9 closing their positions.
141% more capital invested
Capital invested by funds: $1.66M → $4.01M (+$2.34M)
134% more call options, than puts
Call options by funds: $264K | Put options by funds: $113K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
+$3.22M |
| 2 |
RA
RFG Advisory
Birmingham,
Alabama
|
+$347K |
| 3 |
Millennium Management
New York
|
+$178K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$109K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$52.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$199K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$139K |
| 3 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$95K |
| 4 |
EGM
Engineers Gate Manager
New York
|
-$83K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$60.1K |
ALZN Hedge Fund Activity: Q1 2022 in Review
20 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q1 2022, worth a combined $4.01M — up 141% from $1.66M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALZN positions and 9 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Truist Financial, opening a new position worth an estimated $3.22M. The largest seller was Susquehanna International Group, cutting an estimated $199K.
- 20 institutional investors held Alzamend Neuro (ALZN) as of Q1 2022, up from 19 in Q4 2021.
- Funds reported $4.01M of Alzamend Neuro stock for Q1 2022, up 141% quarter-over-quarter.
- 10 funds opened new Alzamend Neuro positions in Q1 2022 and 9 closed out, a net change of +1 holder.
- The largest Alzamend Neuro buyer in Q1 2022 was Truist Financial, an estimated $3.22M added.
- The largest Alzamend Neuro seller in Q1 2022 was Susquehanna International Group, an estimated $199K sold.
Based on aggregated 13F filings for Q1 2022.